ReviewInternational journal of molecular sciences2022
Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- The Role of AXL Signaling and MutantCancers · 2026Review
- Isocitrate dehydrogenase mutations as potential tumour agnostic targets.EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] · 2026Article
- Utilizing bulk and single-cell RNA sequencing to identify potential biomarkers linked to angiogenesis and integrated stress response in chondrosarcoma.Scientific reports · 2026Article
- Precision oncology in the treatment of patients with bone sarcomas: an up-to-date narrative review.Exploration of targeted anti-tumor therapy · 2026Review
- Bimodality imaging as a companion to evaluate antitumour efficacy of TH-302 in experimental chondrosarcoma.EJNMMI research · 2025Article
- Exploring the causal relationship between immune factors and chondrosarcoma: a Mendelian randomization study.Discover oncology · 2025Article
- Causal effect of gut microbiota metabolic pathways on CSAG1 expression in chondrosarcoma: a mendelian randomization analysis.BMC cancer · 2025Article
- Maxillary aggressive chondrosarcoma: A rare and challenging case.Radiology case reports · 2025Article
- DNA methyltransferase 3A: A prognostic biomarker and potential target for immunotherapy in gastric cancer.Medicine · 2025Article
- Impact of the Pretreatment Neutrophil/Lymphocyte Ratio as a Prognostic Factor in Conventional Chondrosarcoma.Indian journal of surgical oncology · 2025Article
- Clinicopathologic and proteomic characteristics of low-grade undifferentiated spindle cell sarcoma.Frontiers in molecular biosciences · 2025Article
- Genetics and Molecular Pathogenesis of the Chondrosarcoma: A Review of the Literature.Current issues in molecular biology · 2024Review
- Multiple enchondromas in Ollier's disease: A case report.Radiology case reports · 2024Article
- RNF2 promotes chondrosarcoma progression by regulating ubiquitination and degradation of CBX7.Cancer & metabolism · 2024Article
- Keratin 17 and Collagen type 1 genes: Esophageal cancer molecular marker discovery and evaluation.The clinical respiratory journal · 2024Article
- Review
- Advancing the Management of Skull Base Chondrosarcomas: A Systematic Review of Targeted Therapies.Journal of personalized medicine · 2024Review
- Article
- Chondrosarcoma With Pulmonary Metastatic Calcifications: A Case Report and Review of the Literature.Cureus · 2024Article
- Construction of novel predictive tools for post-surgical cancer-specific survival probability in patients with primary chondrosarcoma and external validation in Chinese cohorts: a large population-based retrospective study.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to resistance to standard anticancer agents, it is difficult to control the disease progression in patients with metastatic or unresectable chondrosarcoma. Novel therapeutic approaches, such as molecule-targeting drugs and immunotherapy, are required to improve clinical outcomes in patients with advanced chondrosarcoma. Recent studies have suggested several promising biomarkers and therapeutic targets for chondrosarcoma, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.